Canaccord Genuity Maintains Buy on Boston Scientific, Lowers Price Target to $66

Benzinga · 1d ago
Canaccord Genuity analyst William Plovanic maintains Boston Scientific (NYSE:BSX) with a Buy and lowers the price target from $70 to $66.